Synonyms: Example 4 [US2020108083A1] | PF07038124
Compound class:
Synthetic organic
Comment: PF-07038124 is a topically administered PDE4 inhibitor that was developed as a treatment for atopic dermatitis and psoriasis. Its structure was revealed during the 'first disclosure' session at the ACS Spring 2022 meeting. This chemical structure is claimed as Example 4 in Pfizer's patent US2020108083A1 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
PF-07038124 inhibits release of IL-4 and IFNγ from phytohemagglutinin-L-stimulated human peripheral blood mononuclear cells (PBMCs) with IC50 values of 4.1 and 1.1 nM respectively [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|